Eighteen of 22 children had regression, stable disease for more than three months. Some children experienced immunological pseudoprogression. CHICAGO — Peptide vaccination in children with gliomas was well tolerated with evidence of immunological...
Filed under: Press Releases, Research, Cancer, Media Materials, AACR, American Association for Cancer Research, meeting, childhood cancer, Vaccine, 2012 Annual Meeting, AACR Annual Meeting 2012, peptide, gliomas, immunological pseudoprogression, Dr. Ian F. Pollack